Introduction
============

Ocular adnexal marginal zone B cell lymphomas (MZBLs) make up the majority of lymphomas arising from the ocular adnexa. They are characterised histologically by the presence of reactive follicles in up to 64% of cases, sclerosis in up to 20% of cases, and plasma cells in up to 35% of cases.[@b1] Among the inflammatory disorders arising from the ocular adnexa, the IgG4-related lymphoplasmacytic infiltrative disorder is characterised histologically by infiltration by IgG4-positive plasma cells with reactive lymphoid hyperplasia and sclerosing inflammation.[@b2] Ocular adnexal MZBLs are reported to arise in IgG4-related sclerosing dacryoadenitis, indicating a possible link between the two conditions.[@b3] However, clinical information about ocular adnexal MZBLs with IgG4-positive plasma cells is not available. In addition, any causal relationship between ocular adnexal MZBLs with IgG4-positive plasma cells and IgG4-related lymphoplasmacytic infiltrative disorder has not been established.

Thus, the purpose of this study was to determine the clinicopathological characteristics of ocular adnexal MZBLs infiltrated by IgG4-positive plasma cells. To accomplish this goal, we analysed patients with ocular adnexal MZBL with IgG4-positive plasma cells and compared the findings with those in patients with ocular adnexal MZBLs without IgG4-positive plasma cells and patients with ocular adnexal IgG4-related lymphoplasmacytic infiltrative disorder.

Patients and methods
====================

Patients
--------

The procedures used in this study conformed to the tenets of the Declaration of Helsinki and were approved by the Ethics Committee at Nagoya Medical Center, Nagoya, Japan. All patients provided signed informed consent after the procedures and possible outcomes were explained.

Patients with secondary ocular adnexal lymphomas were excluded from this study. The medical records of 114 patients with primary ocular adnexal MZBL who were examined between April 2001 and December 2009 were evaluated. A complete medical history and laboratory data that included the levels of each immunoglobulin and soluble interleukin 2 receptor (sIL-2R) were recorded. The criterion used to diagnose ocular adnexal MZBL with IgG4-positive plasma cells was an IgG4:IgG ratio \>40%. Of the 114 patients, 10 had ocular adnexal MZBLs with IgG4-positive plasma cells (IgG4-related group).

Clinical data
-------------

We recorded the age, gender, laterality, lesion location, systemic evaluations, treatments, response to therapy and clinical follow-up findings of the 10 patients in the IgG4-related group. The pretreatment stage was determined by whole-body CT scans of the neck, chest, abdomen and pelvis. In addition, bone marrow biopsy and gastroscopy were performed. The disease stage at the time of the diagnosis was classified according to that modified for extranodal diseases[@b4] and the American Joint Committee on Cancer classification.[@b5]

Histopathology, immunohistochemistry and molecular genetic analysis
-------------------------------------------------------------------

Biopsy specimens from the ocular adnexal lesions were collected from all patients. Part of the biopsy specimen was embedded in paraffin for conventional histological and immunohistochemical analyses, and the remainder was immediately frozen and used for Southern blot analysis. All biopsy specimens were examined for morphological features, and classified according to the WHO classification.[@b6] The immunophenotype, based mainly on CD20-positive, CD5-negative, CD10-negative, CD23-negative and cyclin D1-negative expression (Dako, Glostrup, Denmark), and κ and λ (by in situ hybridisation; Ventana Medical Systems, Oro Valley, Arizona, USA) was also determined. The IgG-positive and IgG4-positive plasma cells were detected by immunostaining for IgG (polyclonal; Dako) and IgG4 (MC011; The Binding Site Group, Birmingham, England). To determine the number of IgG4-positive or IgG-positive cells, the areas with the highest density of IgG4-positive cells were evaluated. In each specimen, the mean number of IgG4-positive plasma cells was determined from three high-power fields by using methods previously described.[@b3] One high-power field covered an area of 0.196 mm^2^ (magnification ×400; Nikon microscope, Tokyo, Japan). Patients with an IgG4:IgG plasma cell ratio \>40% in a high-power field were placed in the group with ocular adnexal MZBLs with IgG4-positive plasma cells.

Southern blot analysis was performed on the specimens to detect B cell clonality, that is, to determine if immunoglobulin heavy chain gene rearrangements had occurred. A PCR method was performed from the formalin-fixed and paraffin-embedded specimens by methods previously described[@b7] to detect B cell clonality when fresh frozen biopsy samples were not available.

Laboratory data
---------------

Laboratory data were determined from peripheral blood collected from all patients. The serum levels of IgA, IgM, total IgG, IgE and sIL-2R were analysed at the time of diagnosis and the follow-up examinations. Subclasses of IgG (IgG1, 2, 3 and 4) were collected from April 2007 to December 2009. Each subclass of IgG was analysed retrospectively.

Treatments
----------

[Table 1](#tbl1){ref-type="table"} shows the treatments for each patient. For the initial treatment, all patients except for patients 5 and 6 received radiotherapy at a dose of 30 Gy. Following radiotherapy, all patients were carefully monitored, and cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) and/or rituximab, along with the regimen used to treat low-grade non-Hodgkin lymphoma, were administered. This approach was based on the criteria of either rapid enlargement of the systemic tumour or appearance of clinical signs and symptoms, including B symptoms.

###### 

Clinical characteristics of 10 patients with marginal zone B cell lymphoma with IgG4-positive plasma cells

  Patient no.   Age (years)/gender   Laterality   Clinical stage[\*](#table-fn1){ref-type="table-fn"}   Initial treatment   Events during follow-up                                Second treatment                  Outcome and follow-up (months)
  ------------- -------------------- ------------ ----------------------------------------------------- ------------------- ------------------------------------------------------ --------------------------------- --------------------------------
  1             66/M                 Bilateral    T2cN4M0/III                                           Radiation           Malignant transformation to diffuse large cell type    CHOP and rituximab                Died from disease (36)
  2             66/M                 Left         T2cN0M0/IE                                            Radiation           Orbital LPI; gastric LPI                               rituximab                         AOD (97)
  3             67/F                 Left         T2cN0M0/IE                                            Radiation           Gastric carcinoma and LPI, developing TNM staging N4   Gastrectomy, CHOP and rituximab   AOD (70)
  4             75/M                 Left         T2cN0M0/IE                                            Radiation           Developing TNM staging N4                              ND                                Died from other cause (65)
  5             64/F                 Left         T2bN0M0/IE                                            CP                  Developing TNM staging N3                              ND                                AWD (82)
  6             70/M                 Right        T2cN4M0/III                                           Excision            None                                                   ND                                AWD (13)
  7             61/M                 Left         T2cN0M0/IE                                            Radiation           Developing TNM staging N4                              ND                                AWD (73)
  8             90/M                 Left         T2cN4M0/III                                           Radiation           None                                                   ND                                AOD (9)
  9             65/M                 Right        T2bN0M0/IE                                            Radiation           None                                                   ND                                AOD (26)
  10            64/M                 Right        T2cN0M0/IE                                            Radiation           None                                                   ND                                AOD (26)

American Joint Committee on Cancer staging and Ann Arbor staging.

AOD, alive without disease; AWD, alive with disease; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; LPI, lymphoplasmacytic infiltrations; TNM, tumour, node, metastases.

Statistical analyses
--------------------

We compared the incidence of sclerosing and follicular lesions in the IgG4-related and IgG4-unrelated groups using the χ^2^ or Fisher\'s exact tests. The laboratory results were compared between the IgG4-related group and 61 consecutive patients in the IgG4-unrelated group, as were those between the IgG4-related group and 10 patients with ocular adnexal IgG4-related lymphoplasmacytic disorder (IgG4-related inflammatory group), all using the Mann--Whitney test. All statistical analyses were performed on a personal computer with the SPSS statistical package for Windows (Version 12.0; SPSS, Chicago, Illinois, USA). A p value \<0.05 was considered to be statistically significant.

Results
=======

Clinical data
-------------

Among the 114 patients with ocular adnexal MZBLs, 10 (9%) met the criterion based on the immunostaining for IgG4 and IgG. [Table 1](#tbl1){ref-type="table"} shows the distribution of the age, gender, laterality, American Joint Committee on Cancer staging, Ann Arbor clinical staging, initial and second treatments and outcomes for the IgG4-related group. The findings for the two patients with polyclonal hypergammaglobulinaemia have been reported previously.[@b8]

Histopathology, immunohistochemistry and molecular genetic analysis
-------------------------------------------------------------------

All 114 biopsy specimens of the ocular adnexa were diagnosed as MZBLs based on histopathological and immunohistochemical results. The histological study of ocular adnexal MZBLs showed sclerosing changes in 48% (55/114) of the cases and reactive follicles in 39% (44/114).

In the IgG4-related group ([figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}), the histological study showed sclerosing lesions in all (10/10) and reactive follicles in 80% (8/10). The IgG4:IgG ratio for biopsy samples of the IgG4-related group ranged from 1.0 to 0.43, in contrast to that of the IgG4-unrelated group ([figure 3](#fig3){ref-type="fig"}), which ranged from 0.2 to 0. All biopsy specimens showed light-chain restrictions by in situ hybridisation and also showed immunoglobulin heavy-chain gene rearrangement by Southern blot analysis (data not available for patients 1 and 2).

![Initial and second biopsy specimens for recurrent lesions of patient 2. (A) CT images showing the tumour located in the left posterior orbit (left) at the time of diagnosis and recurring diffusely in the left posterior orbit (right) 53 months after radiotherapy. (B) Initial biopsy specimen showing proliferation of lymphoid cells with abundant follicles and sclerosis. H&E staining, original magnification ×40. (C) Immunostaining for λ (left) and κ (right) of the initial biopsy specimen shows light-chain restriction. In situ hybridisation, original magnification ×40. (D) Immunostaining for IgG4 shows IgG4-positive plasma cells. The IgG4:IgG ratio was 0.43. Immunoperoxidase staining, original magnification ×400. (E) Second biopsy samples for recurrent lesions showing reactive lymphoplasmacytic proliferations. H&E staining, original magnification ×200. Immunostaining for IgG4 shows IgG4-positive plasma cells in the recurrent lesions. Right, the IgG4:IgG ratio was 0.62. Immunoperoxidase staining, original magnification ×200. (F) Immunostaining for λ (left) and κ (right) does not show light-chain restrictions. In situ hybridisation, original magnification ×200. Southern blot analysis did not detect heavy-chain gene rearrangement.](jclinpath82156fig1){#fig1}

![Histological and immunohistochemical findings in conjunctival marginal zone B cell lymphoma with IgG4-positive plasma cells from patient 6. (A) Salmon-pink mass lesions on the left bulbar conjunctiva. CT image shows medial rectus muscle enlargement (insert). (B) Histological study shows dense lymphocytic proliferation with sclerosis and follicles. H&E staining, original magnification ×40. (C) Immunostaining for λ (left) and κ (right) shows light-chain restriction. Southern blot analysis shows immunoglobulin heavy-chain gene rearrangement. In situ hybridisation, original magnification ×40. (D) Higher magnification shows small and medium-sized lymphocytes with plasma cells and sclerosis. H&E staining, original magnification ×400. (E) Another higher magnification shows lymphoplasmacytic infiltrations with abundant sclerosing lesions. H&E staining, original magnification ×400. (F) Immunostaining for IgG4 reveals IgG4-positive plasma cells in the lymphoplasmacytic lesions. The IgG4:IgG ratio was 0.53. Immunoperoxidase staining, original magnification ×400.](jclinpath82156fig2){#fig2}

![Findings in a 67-year-old man with bilateral conjunctival marginal zone B cell lymphoma without IgG4-positive plasma cells. (A) Salmon-pink mass lesions proliferate on the left bulbar conjunctiva. (B) Histology (left) of the lesion shows lymphoid cells proliferating without sclerosis and follicles. H&E staining, original magnification ×100. The specimen showed light-chain restriction by in situ hybridisation and immunoglobulin heavy-chain gene rearrangement by Southern blot analysis. Immunostaining for IgG4 (right) does not show IgG4-positive plasma cells. Immunoperoxidase staining, original magnification ×100.](jclinpath82156fig3){#fig3}

The ocular adnexal recurrent lesion for patient 2 showed lymphoplasmacytic proliferation with IgG4-positive plasma cells and did not show either light-chain restriction or immunoglobulin heavy-chain gene rearrangement ([figure 1](#fig1){ref-type="fig"}). Gastric biopsy samples during follow-up periods from patients 2 and 3 showed reactive lymphoid proliferation with IgG4-positive plasma cells ([figure 4](#fig4){ref-type="fig"}). Immunostaining did not show light-chain restriction by in situ hybridisation. PCR showed immunoglobulin heavy-chain gene rearrangement from the gastric sample of patients 2 and 3.

![Gastric biopsy samples of patients 2 and 3. (A) Histology of patient 2 shows lymphoplasmacytic proliferations in the stomach. H&E staining, original magnification ×100. Immunostaining did not show light-chain restriction; however, the analysis of the specimen on PCR showed immunoglobulin heavy-chain gene rearrangement. (B) Higher magnification (left) shows lymphoplasmacytic infiltrations. H&E staining, original magnification ×400. Immunostaining for IgG4 (right) shows IgG4-positive plasma cells. The IgG4:IgG ratio was 0.67. Immunoperoxidase staining, original magnification ×400. (C) Histology of patient 3 shows lymphoplasmacytic proliferations. H&E staining, original magnification ×100. Immunostaining did not show light-chain restriction; however, the analysis of the specimen on PCR showed immunoglobulin heavy-chain gene rearrangement. (D) Higher magnification (left) shows lymphoplasmacytic infiltrations. H&E staining, original magnification ×400. Immunostaining for IgG4 (right) showed IgG4-positive plasma cells. The IgG4:IgG ratio was 0.70. Immunoperoxidase staining, original magnification ×400.](jclinpath82156fig4){#fig4}

Statistical analyses showed that biopsy samples from the IgG4-related group were significantly associated with sclerosing infiltrations (100% vs 43%; p=0.0004; Fisher\'s exact test), reactive follicles (80% vs 35%; p=0.01; Fisher\'s exact test) compared with those from the IgG4-unrelated group.

Systemic evaluations
--------------------

Three patients (30%) had systemic lymphadenopathy at the time of diagnosis ([figure 5](#fig5){ref-type="fig"}) involving the chest (patients 6 and 8), axillae (patient 6), and abdomen (patient 1). In contrast, among the IgG4-unrelated group, seven (7%) had systemic lymphadenopathy at the time of diagnosis. The IgG4-related group had significant systemic lymphadenopathy at the time of diagnosis compared with that of the IgG4-unrelated group (30% vs 7%; p=0.04; Fisher\'s exact test). Patients 3, 4, 5 and 7 had stage I disease but later developed systemic lymphadenopathy that involved the chest (patients 3, 4 and 7), the axillae (patients 3 and 5), abdomen (patients 3 and 4) and pelvis (patient 4).

![Fluorodeoxyglucose F-18 (FDG) positron emission tomography at the initial examination of patient 6 (A) whose ocular data are presented in [figure 3](#fig3){ref-type="fig"} (B). FDG positron emission tomography of patient 6 showed accumulation of FDG in the right ocular adnexa, chest and left axillae (arrowheads) at the time of the diagnosis. Fusion images demonstrate not only swelling of several bronchomediastinal lymph nodes (arrows), but also the metabolic activity of the lesions. In contrast, the patient in [figure 3](#fig3){ref-type="fig"} shows none of the accumulations including in the ocular adnexa.](jclinpath82156fig5){#fig5}

Treatment and outcome
---------------------

[Table 1](#tbl1){ref-type="table"} shows the results of the systemic evaluations, treatment and outcome. Following radiotherapy, all patients achieved complete regression in the irradiated field. Patients 2 and 3 relapsed in the irradiation field after 65 and 24 months, respectively, and also had IgG4-positive lymphoplasmacytic proliferations in the stomach. Patient 3 additionally developed gastric carcinoma. Patient 2 received rituximab treatment, and the recurrent lesion regressed but then gradually relapsed again. Patient 3 received gastrectomy and rituximab and CHOP therapy, and had no evidence of the disease at the final examination.

Laboratory data
---------------

[Table 2](#tbl2){ref-type="table"} presents the mean serum levels of IgA, IgM, IgG1--4, IgE and sIL-2R receptor for the 10 patients in the IgG4-related group, the 61consecutive patients in the IgG4-unrelated group, and the 10 patients in the IgG4-related inflammatory group. The serum levels of IgG, IgG1, IgG4, IgE and sIL-2R receptor in the IgG4-related group were significantly higher than those in the IgG4-unrelated group ([table 2](#tbl2){ref-type="table"}; p=0.003, p=0.009, p\<0.0001, p\<0.0001 and p=0.0007, respectively; Mann--Whitney test). In contrast, the serum levels of IgM were significantly lower than those in the IgG4-unrelated group (p=0.02; Mann--Whitney test), although, for the two groups, serum levels of IgM were within normal limits. Between the IgG4-related group and the IgG4-related inflammatory group, neither immunoglobulin nor sIL-2R levels differed significantly.

###### 

Serological data of patients with ocular adnexal MZBL with or without IgG4-positive plasma cells, and patients with ocular adnexal IgG4-related lymphoplasmacytic disorder

  Serological data (normal range)   IgG4-related group, n=10   IgG4-unrelated group, n=61   IgG4-related inflammatory group, n=10   p Value[\*](#table-fn2){ref-type="table-fn"}   p Value[†](#table-fn3){ref-type="table-fn"}
  --------------------------------- -------------------------- ---------------------------- --------------------------------------- ---------------------------------------------- ---------------------------------------------
  IgA (110--410 mg/dl)              214 (109)                  228 (103)                    229 (149)                               0.6                                            0.7
  IgM (33--190 mg/dl)               102 (58)                   157 (93)                     78 (58)                                 0.02                                           0.09
  Total IgG (870--1700 mg/dl)       2432 (1944)                1287 (406)                   2732 (1749)                             0.003                                          1.0
  IgG1 (320--748 mg/dl)             858 (193)                  655 (190)                    1047 (418)                              0.009                                          0.4
  IgG2 (208--754 mg/dl)             607 (232)                  494 (172)                    836 (465)                               0.2                                            0.4
  IgG3 (7--88 mg/dl)                86 (72)                    44 (35)                      66 (47)                                 0.2                                            0.9
  IgG4 (5--105 mg/dl)               415 (295)                  48 (46)                      901 (890)                               \<0.0001                                       0.2
  IgE (\<170 IU/ml)                 1581 (1717)                293 (509)                    1020 (1159)                             \<0.0001                                       0.2
  sIL-2R (135--483 U/ml)            943 (525)                  465 (392)                    941 (579)                               0.0007                                         0.9

Values are mean (standard deviation).

IgG4-related group: patients having ocular adnexal MZBL with IgG4-positive plasma cells; IgG4-related inflammatory group: patients with ocular adnexal IgG4-related lymphoplasmacytic infiltrative disorder; IgG4-unrelated group: patients having ocular adnexal MZBL without IgG4-positive plasma cells.

IgG4-related group versus IgG4-unrelated group.

IgG4-related group versus IgG4-related inflammatory group.

MZBL, marginal zone B cell lymphoma; sIL-2R, soluble interleukin-2 receptor.

Discussion
==========

Nine per cent of the cases of ocular adnexal MZBLs consisted of IgG4-positive plasma cells with sclerosing and reactive follicular lesions. Sclerosing and reactive follicles had a relatively high incidence in our cases of ocular adnexal MZBLs. However, on the basis of the unique systemic and serological characteristics of the IgG4-related group, we suggest that IgG4-positive plasma cells with sclerosing and reactive follicles are specific inflammatory lesions in ocular adnexal MZBLs.

IgG4-positive plasma cell infiltrations with sclerosing and reactive follicles in the IgG4-related group were similar to those already published for the IgG4-related inflammatory group,[@b2] although they are distinct different clinical entities. Interestingly, gastric biopsy samples in the IgG4-related group revealed IgG4-positive lymphoplasmacytic infiltrations. A close association of histology and serum abnormalities between the IgG4-related group and the IgG4-related inflammatory group suggests that the pathogenesis of IgG4-positive plasma cell infiltrations into ocular adnexal MZBLs may be induced by conditions similar to both. Thus, pathogenesis of IgG4-positive plasma cell infiltrations into ocular adnexal MZBLs may be correlated with a systemic condition that induces unique serum abnormalities.

Ocular adnexal MZBLs with IgG4-positive plasma cells must be differentiated from ocular adnexal IgG4-related lymphoplasmacytic disorder. Our biopsy samples showed not only histological MZBLs but also B cell clonality. These analyses support the identification of our biopsy samples as MZBLs.

Ocular adnexal MZBLs with IgG4-positive plasma cells were typically associated with elevated levels of IgG4, IgE and sIL-2R, and polyclonal hypergammaglobulinaemia. One plausible hypothesis for these serological and immunological abnormalities may be that they are caused by in vivo activation of the immune system by activated Th2 cells. Activated Th2 cells produce IgE and induce polyclonal B cell activation,[@b9] and IgG4 is induced by a modified Th2 response.[@b10] Elevated levels of sIL-2R reflect the in vivo activation of the immune system.[@b11] Thus, the cause of the serological abnormalities in the IgG4-related group may be correlated with activated Th2 cells.

Our study has several limitations. First, each subclass of IgG was collected retrospectively, and this may have led to some bias. Second, there were discrepancies in the B cell clonality between immunohistochemistry and PCR from a gastric sample of patients 2 and 3. This may have been an incipient clone with a background of IgG4-positive lymphoplasmacytic infiltrations, although the result of the PCR could also be a false positive.

In conclusion, sclerosing and reactive follicular lesions with IgG4-positive plasma cells infiltrated into ocular adnexal MZBLs in 9% of cases. Patients having MZBL with IgG4-positive lymphoplasmacytic infiltrations characteristically had elevated serum levels of IgG4, IgE and sIL-2R, and systemic IgG4-positive plasma cell infiltrations, such as in the recurrent lesion and stomach. We hypothesise that the pathogenesis of IgG4-positive plasma cell infiltrations into ocular adnexal MZBLs is correlated with a systemic condition that induces unique serum abnormalities.

###### Take-home messages

-   Ocular adnexal marginal zone B cell lymphoma (MZBL) infiltrated by IgG4-positive plasma cells has significant sclerosis in the lesions.

-   Patients with MZBL infiltrated by IgG4-positive plasma cells have unique serum abnormalities, that is, elevated levels of IgG4, IgE and soluble interleukin-2 receptor, and polyclonal hypergammaglobulinaemia.

-   Patients with MZBL infiltrated by IgG4-positive plasma cells also have reactive IgG4-positive lymphoplasmacytic infiltrations in the recurrent lesion and in the stomach.
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